Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HYPERION DEFI, INC.EYEN · Entity 7220 | Director | April 21, 2025 | April 29, 2025 |
| Tonix Pharmaceuticals Holding Corp.TNXP · Entity 6169 | Director | June 12, 2018 | June 13, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HYPERION DEFI, INC.
Report date April 21, 2025 · Filed April 29, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001SEC Table I · non-derivative | Direct | 9,950 |
Reported balance
After 2025-04-21 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-04-21 · Grant · Acquired 8,000 · Balance 9,950 F1: Represents restricted stock units that will fully vest upon the closing of the Issuer's proposed business combination with Betaliq, Inc. Vesting is subject to the Reporting Person's continued service to the Issuer. F2: On January 31, 2025, the Issuer effected a reverse stock split of its common stock at a ratio of 1-for-80 (the "Reverse Split"). The Reporting Person's ownership of the Issuer's securities has been adjusted to reflect the impact of the Reverse Split. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that will fully vest upon the closing of the Issuer's proposed business combination with Betaliq, Inc. Vesting is subject to the Reporting Person's continued service to the Issuer.
F2: On January 31, 2025, the Issuer effected a reverse stock split of its common stock at a ratio of 1-for-80 (the "Reverse Split"). The Reporting Person's ownership of the Issuer's securities has been adjusted to reflect the impact of the Reverse Split.
Tonix Pharmaceuticals Holding Corp.
Report date June 12, 2018 · Filed June 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2028-06-12 | Direct | 20,000 |
Reported balance
After 2018-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-12 · Grant · Acquired 20,000 · Balance 20,000 F1: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 21, 2025 Filed Apr 23, 2025 21:34 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-038174 · tm2512986-5_4seq1.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,953 F1 · shares: Represents restricted stock units that will fully vest upon the closing of the Issuer's proposed business combination with Betaliq, Inc. Vesting is subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: On January 31, 2025, the Issuer effected a reverse stock split of its common stock at a ratio of 1-for-80 (the "Reverse Split"). The Reporting Person's ownership of the Issuer's securities has been adjusted to reflect the impact of the Reverse Split. Read SEC document |
| April 21, 2025 Filed Apr 29, 2025 19:56 UTC Amendment | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-041551 · tm2513522-4_4aseq1.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,950 F1 · shares: Represents restricted stock units that will fully vest upon the closing of the Issuer's proposed business combination with Betaliq, Inc. Vesting is subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: On January 31, 2025, the Issuer effected a reverse stock split of its common stock at a ratio of 1-for-80 (the "Reverse Split"). The Reporting Person's ownership of the Issuer's securities has been adjusted to reflect the impact of the Reverse Split. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 15:06 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantStock Option (right to buy) · Derivative | 85,106 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001104659-24-071706 · tm2417330-4_4seq1.xml · derivative · entry 2 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,106 Underlying: Common Stock · 85,106 shares Expires 2034-06-12 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of June 12, 2025 or the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 15:06 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 61,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-071706 · tm2417330-4_4seq1.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,266 F1 · shares: Represents restricted stock units that fully vest on the earlier of June 12, 2025 or the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 18:42 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantStock Option (right to buy) · Derivative | 24,691 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001104659-23-076458 · tm2320271-3_4seq1.xml · derivative · entry 2 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,691 Underlying: Common Stock · 24,691 shares Expires 2033-06-27 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of June 27, 2024 or the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 18:42 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 17,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-076458 · tm2320271-3_4seq1.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,785 F1 · shares: Represents restricted stock units that fully vest on the earlier of June 27, 2024 or the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| May 26, 2023 Filed May 30, 2023 10:13 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | PurchaseCommon Stock, par value $.0001 | 3,000 | $2.49 | $7,469.70 |
DisclosureSEC source: 0001104659-23-065738 · tm2317274-1_4seq1.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,544 Read SEC document |
| May 15, 2023 Filed May 16, 2023 15:08 UTC Amendment | HYPERION DEFI, INC. EYEN · Entity 7220 | PurchaseCommon Stock, par value $.0001 | 4,000 | $3.39 | $13,560.00 |
DisclosureSEC source: 0001104659-23-061340 · tm2315948-1_4aseq1.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,544 Read SEC document |
| May 15, 2023 Filed May 16, 2023 12:11 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | PurchaseCommon Stock, par value $.0001 | 4,000 | $3.39 | $13,560.00 |
DisclosureSEC source: 0001104659-23-061264 · tm2315948-1_4seq1.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,544 Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 14:24 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantStock Option (right to buy) · Derivative | 30,769 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001415889-22-006809 · form4-06212022_110620.xml · derivative · entry 2 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,769 Underlying: Common Stock · 30,769 shares Expires 2032-06-16 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 14:24 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 22,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-006809 · form4-06212022_110620.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,544 F1 · shares: Represents restricted stock units that fully vest on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| May 18, 2022 Filed May 19, 2022 08:27 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | PurchaseCommon Stock, par value $.0001 | 7,000 | $2.03 | $14,231.70 |
DisclosureSEC source: 0001415889-22-005263 · form4-05192022_050552.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,322 Read SEC document |
| March 31, 2022 Filed Mar 31, 2022 21:24 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | PurchaseCommon Stock, par value $.0001 | 4,000 | $3.12 | $12,460.00 |
DisclosureSEC source: 0001415889-22-003528 · form4-03312022_060356.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,322 Read SEC document |
| November 17, 2021 Filed Nov 22, 2021 09:14 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantStock Option (right to buy) · Derivative | 9,653 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001415889-21-005361 · form4-11222021_061107.xml · derivative · entry 2 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,653 Underlying: Common Stock · 9,653 shares Expires 2031-11-17 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| November 17, 2021 Filed Nov 22, 2021 09:14 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 6,963 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005361 · form4-11222021_061107.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,322 F1 · shares: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| November 01, 2021 Filed Nov 1, 2021 17:05 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | PurchaseCommon Stock, par value $.0001 | 4,000 | $3.83 | $15,314.40 |
DisclosureSEC source: 0001415889-21-005035 · form4-11012021_021155.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,359 Read SEC document |
| May 28, 2021 Filed May 28, 2021 16:09 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | PurchaseCommon Stock, par value $.0001 | 3,000 | $4.76 | $14,268.30 |
DisclosureSEC source: 0001638599-21-000474 · doc4_7224.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,359 Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:16 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantStock Option (right to buy) · Derivative | 9,820 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001104659-20-105232 · tm2030853d2_4.xml · derivative · entry 2 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,820 Underlying: Common Stock · 9,820 shares Expires 2030-09-11 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of September 11, 2020 or the date of the Issuer's 2021 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:16 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 7,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-105232 · tm2030853d2_4.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,359 F1 · shares: Represents restricted stock units that vest on the earlier of September 11, 2020 or the date of the Issuer's 2021 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 17:21 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantStock Option (right to buy) · Derivative | 9,057 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001638599-19-000797 · doc4_6259.xml · derivative · entry 2 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,057 Underlying: Common Stock · 9,057 shares Expires 2029-08-16 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of August 16, 2020 or the date of the Issuer's 2020 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 17:21 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 8,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-000797 · doc4_6259.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,071 F1 · shares: Represents restricted stock units that vest on the earlier of August 16, 2020 or the date of the Issuer's 2020 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| September 19, 2018 Filed Sep 20, 2018 16:17 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | PurchaseCommon Stock, par value $.0001 | 3,000 | $4.78 | $14,340.00 |
DisclosureSEC source: 0001638599-18-001117 · doc4_5697.xml · nonDerivative · entry 2 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,033 F1 · price: This transaction was executed in multiple trades ranging from $4.75 to $4.7885. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 16:17 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | PurchaseCommon Stock, par value $.0001 | 1,000 | $4.80 | $4,800.00 |
DisclosureSEC source: 0001638599-18-001117 · doc4_5697.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,033 Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 18:12 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantStock Option (right to buy) · Derivative | 4,465 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001638599-18-000820 · doc4_5549.xml · derivative · entry 2 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,465 Underlying: Common Stock · 4,465 shares Expires 2028-07-24 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of July 24, 2019 or the date of the Issuer's 2019 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 18:12 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 4,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000820 · doc4_5549.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,033 F1 · shares: Represents restricted stock units that vest on the earlier of July 24, 2019 or the date of the Issuer's 2019 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| June 12, 2018 Filed Jun 13, 2018 21:15 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001615774-18-005233 · s110813_form4.xml · derivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-12 F1 · price: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan. Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 21:58 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionCommon Stock, $0.001 par value | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001529 · s109198_form4.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were acquired upon the vesting and settlement of certain restricted stock units. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 21:00 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001615774-17-003293 · s106635_form4.xml · derivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-20 F1 · price: The option was granted pursuant to the Issuer's 2017 Stock Incentive Plan. Read SEC document |
| May 27, 2017 Filed Mar 9, 2018 20:30 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001746 · s109295_form4.xml · derivative · entry 4 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On May 27, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date. F3 · derivative.expiration_date: On May 27, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date. Read SEC document |
| May 27, 2017 Filed Mar 9, 2018 20:30 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionCommon Stock, $0.001 par value | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001746 · s109295_form4.xml · nonDerivative · entry 1 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. F2 · shares: This transaction was reported on a previous Form 4, filed on February 28, 2018, which failed to correctly state the number of shares beneficially owned by the reporting person on the transaction date. Read SEC document |
| February 09, 2017 Filed Mar 9, 2018 20:30 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001746 · s109295_form4.xml · derivative · entry 5 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On February 9, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date. F4 · derivative.expiration_date: On February 9, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date. Read SEC document |
| February 09, 2017 Filed Mar 9, 2018 20:30 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionCommon Stock, $0.001 par value | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001746 · s109295_form4.xml · nonDerivative · entry 2 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 25, 2016 Filed Mar 9, 2018 20:30 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001746 · s109295_form4.xml · derivative · entry 6 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On February 25, 2015, the reporting person was granted 600 restricted stock units, vesting in on the first anniversary of the grant date. F5 · derivative.expiration_date: On February 25, 2015, the reporting person was granted 600 restricted stock units, vesting in on the first anniversary of the grant date. Read SEC document |
| February 25, 2016 Filed Mar 9, 2018 20:30 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionCommon Stock, $0.001 par value | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001746 · s109295_form4.xml · nonDerivative · entry 3 MATHER CHARLES E IV · CIK 0001563422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.